Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications
Actas Dermosifiliogr. 2014 Jan-Feb;105(1):31-44.
doi: 10.1016/j.ad.2012.08.003.
Epub 2012 Nov 23.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Dermatología, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España. Electronic address: jmcarrascosac@hotmail.com.
- 2 Servicio de Dermatología, Hospital de Manacor, Manacor, Mallorca, España.
- 3 Complejo Hospitalario Universitario de La Coruña, La Coruña, España.
- 4 Servicio de Dermatología, Hospital Universitario Reina Sofía, Madrid, España.
Abstract
Obesity, particularly abdominal obesity, is currently considered a chronic low-grade inflammatory condition that plays an active role in the development of the pathophysiologic phenomena responsible for metabolic syndrome and cardiovascular disease through the secretion of proinflammatory adipokines and cytokines. In recent years clear genetic, pathogenic, and epidemiologic links have been established between psoriasis and obesity, with important implications for health. The relationship between the 2 conditions is probably bidirectional, with obesity predisposing to psoriasis and psoriasis favoring obesity. Obesity also has important implications in the treatment of psoriasis, such as a greater risk of adverse effects with conventional systemic drugs and reduced efficacy and/or increased cost with biologic agents, for which dosage should be adjusted to the patient's weight.
Keywords:
Adipocinas; Adipokine; Metabolic syndrome; Obesidad; Obesity; Psoriasis; Síndrome metabólico; Terapéutica; Therapy.
Copyright © 2012 Elsevier España, S.L. and AEDV. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adipocytes / metabolism
-
Adipocytes / pathology
-
Adipokines / metabolism
-
Adipokines / physiology
-
Adipose Tissue / metabolism
-
Anti-Inflammatory Agents / administration & dosage
-
Anti-Inflammatory Agents / economics
-
Anti-Inflammatory Agents / pharmacokinetics
-
Anti-Inflammatory Agents / therapeutic use
-
Antirheumatic Agents / administration & dosage
-
Antirheumatic Agents / economics
-
Antirheumatic Agents / pharmacokinetics
-
Antirheumatic Agents / therapeutic use
-
Body Weight / drug effects
-
Cardiovascular Diseases / etiology
-
Cardiovascular Diseases / physiopathology
-
Causality
-
Cell Adhesion Molecules / metabolism
-
Cell Communication
-
Cytokines / metabolism
-
Cytokines / physiology
-
Disease Susceptibility
-
Dose-Response Relationship, Drug
-
Fatty Acids, Nonesterified / metabolism
-
Hormones / physiology
-
Humans
-
Immunologic Factors / administration & dosage
-
Immunologic Factors / economics
-
Immunologic Factors / pharmacokinetics
-
Immunologic Factors / therapeutic use
-
Inflammation / complications*
-
Inflammation / drug therapy
-
Inflammation / physiopathology
-
Lymphocytes / pathology
-
Metabolic Syndrome / etiology
-
Metabolic Syndrome / physiopathology
-
Models, Biological
-
Obesity / complications
-
Obesity / immunology*
-
Obesity / physiopathology
-
PUVA Therapy
-
Psoriasis / complications
-
Psoriasis / drug therapy
-
Psoriasis / immunology*
Substances
-
Adipokines
-
Anti-Inflammatory Agents
-
Antirheumatic Agents
-
Cell Adhesion Molecules
-
Cytokines
-
Fatty Acids, Nonesterified
-
Hormones
-
Immunologic Factors